Samuel Agresta is Chief Medical Officer at Foghorn Therapeutics Inc. (FHTX). They have made 1 open-market trade across 1 company since 2023, most recently 2023-08-16.
CIK 0001748961
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| FHTX | 311,297 | $579K |
Shares reported on the most recent Form 4, priced at the 2023-08-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FHTX | SELL | 2023-08-16 | 2023-08-18 | $8.25 | $5.1M | -1.5% | -22.6% | -51.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.